Pierre Fabre acquired several assets in the preclinical and early discovery phases from the US biotechnology company Igenica Biotherapeutics, including innovative immunotherapies targeting immune checkpoints that may reverse the resistance to existing immunotherapies. Igenica Biotherapeutics’ activities focuses on antibodies in the field of immune-oncology and antibody-drug conjugates (ADCs) for the treatment of cancer.